Search Results - "Brentjens, J"

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy by Khalil, Danny N., Smith, Eric L., Brentjens, Renier J., Wolchok, Jedd D.

“…Key Points Cancer immunotherapies have the potential to generate robust antitumour responses; this can be achieved through several methods, such as modulatory…”
Get full text

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia by Park, Jae H, Rivière, Isabelle, Gonen, Mithat, Wang, Xiuyan, Sénéchal, Brigitte, Curran, Kevin J, Sauter, Craig, Wang, Yongzeng, Santomasso, Bianca, Mead, Elena, Roshal, Mikhail, Maslak, Peter, Davila, Marco, Brentjens, Renier J, Sadelain, Michel

“…CAR T cells expressing anti-CD19 and signaling molecules CD28 and CD3-zeta chain induced complete remission in 83% of patients with refractory ALL. Patients…”
Get full text

Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy by Yeku, Oladapo O, Brentjens, Renier J

“…Chimaeric antigen receptor (CAR) T-cells are T-cells that have been genetically modified to express an artificial construct consisting of a synthetic T-cell…”
Get more information

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy by Khalil, Danny N, Smith, Eric L, Brentjens, Renier J, Wolchok, Jedd D

Get full text

Toxicity and management in CAR T-cell therapy by Bonifant, Challice L, Jackson, Hollie J, Brentjens, Renier J, Curran, Kevin J

“…T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated…”
Get full text

IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models by Jaspers, Janneke E, Khan, Jonathan F, Godfrey, William D, Lopez, Andrea V, Ciampricotti, Metamia, Rudin, Charles M, Brentjens, Renier J

“…Patients with small cell lung cancer (SCLC) generally have a poor prognosis and a median overall survival of only about 13 months, indicating the urgent need…”
Get full text

Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells by Geyer, Mark B, Brentjens, Renier J

“…Abstract The past several years have been marked by extraordinary advances in clinical applications of immunotherapy. In particular, adoptive cellular therapy…”
Get full text

Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages by Song, Mei, Yeku, Oladapo O., Rafiq, Sarwish, Purdon, Terence, Dong, Xue, Zhu, Lijing, Zhang, Tuo, Wang, Huan, Yu, Ziqi, Mai, Junhua, Shen, Haifa, Nixon, Briana, Li, Ming, Brentjens, Renier J., Ma, Xiaojing

“…Immunosuppressive tumor microenvironment (TME) and ascites-derived spheroids in ovarian cancer (OC) facilitate tumor growth and progression, and also pose…”
Get full text

GPRC5D-Targeted CAR T Cells for Myeloma by Mailankody, Sham, Devlin, Sean M., Landa, Jonathan, Nath, Karthik, Diamonte, Claudia, Carstens, Elizabeth J., Russo, Douglas, Auclair, Romany, Fitzgerald, Lisa, Cadzin, Briana, Wang, Xiuyan, Sikder, Devanjan, Senechal, Brigitte, Bermudez, Vladimir P., Purdon, Terence J., Hosszu, Kinga, McAvoy, Devin P., Farzana, Tasmin, Mead, Elena, Wilcox, Jessica A., Santomasso, Bianca D., Shah, Gunjan L., Shah, Urvi A., Korde, Neha, Lesokhin, Alexander, Tan, Carlyn R., Hultcrantz, Malin, Hassoun, Hani, Roshal, Mikhail, Sen, Filiz, Dogan, Ahmet, Landgren, Ola, Giralt, Sergio A., Park, Jae H., Usmani, Saad Z., Rivière, Isabelle, Brentjens, Renier J., Smith, Eric L.

“…In an early-phase study involving 17 patients with highly refractory multiple myeloma, CAR T-cell therapy with specificity for a G protein–coupled receptor…”
Get full text

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance by Boyiadzis, Michael M, Dhodapkar, Madhav V, Brentjens, Renier J, Kochenderfer, James N, Neelapu, Sattva S, Maus, Marcela V, Porter, David L, Maloney, David G, Grupp, Stephan A, Mackall, Crystal L, June, Carl H, Bishop, Michael R

“…Chimeric Antigen Receptor (CAR) T cell therapies - adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have…”
Get full text

Author Correction: T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection by Stephan, Matthias. T, Ponomarev, Vladimir, Brentjens, Renier .J, Chang, Alex. H, Dobrenkov, Konstantin. V, Heller, Glenn, Sadelain, Michel

Get full text

CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function by Kuhn, Nicholas F., Lopez, Andrea V., Li, Xinghuo, Cai, Winson, Daniyan, Anthony F., Brentjens, Renier J.

“…While effective in specific settings, adoptive chimeric antigen receptor (CAR) T cell therapy for cancer requires further improvement and optimization. Our…”
Get full text

Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts by BRENTJENS, Renier J, SANTOS, Elmer, NIKHAMIN, Yan, YEN, Raymond, MATSUSHITA, Maiko, LA PERLE, Krista, QUINTAS-CARDAMA, Alfonso, LARSON, Steven M, SADELAIN, Michel

“…Purpose: Human T cells targeted to the B cell–specific CD19 antigen through retroviral-mediated transfer of a chimeric antigen receptor (CAR), termed 19z1,…”
Get full text

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen by Rafiq, S, Purdon, T J, Daniyan, A F, Koneru, M, Dao, T, Liu, C, Scheinberg, D A, Brentjens, R J

“…CD19-directed chimeric antigen receptor (CAR) T cells are clinically effective in a limited set of leukemia patients. However, CAR T-cell therapy thus far has…”
Get full text

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition by Yeku, Oladapo O, Rao, Thapi Dharma, Laster, Ian, Kononenko, Artem, Purdon, Terence J, Wang, Pei, Cui, Ziyou, Liu, Hong, Brentjens, Renier J, Spriggs, David

“…Immunotherapy for ovarian cancer is an area of intense investigation since the majority of women with relapsed disease develop resistance to conventional…”
Get full text

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor by Sadelain, Michel, Maher, John, Brentjens, Renier J, Gunset, Gertrude, Rivière, Isabelle

“…Artificial receptors provide a promising approach to target T lymphocytes to tumor antigens. However, the receptors described thus far produce either an…”
Get full text

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia by Maslak, Peter G., Dao, Tao, Bernal, Yvette, Chanel, Suzanne M., Zhang, Rong, Frattini, Mark, Rosenblat, Todd, Jurcic, Joseph G., Brentjens, Renier J., Arcila, Maria E., Rampal, Raajit, Park, Jae H., Douer, Dan, Katz, Laura, Sarlis, Nicholas, Tallman, Martin S., Scheinberg, David A.

“…A National Cancer Institute consensus study on prioritization of cancer antigens ranked the Wilms tumor 1 (WT1) protein as the top immunotherapy target in…”
Get full text

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy by HOLLYMAN, Daniel, STEFANSKI, Jolanta, SADELAIN, Michel, BRENTJENS, Renier J, RIVIERE, Isabelle, PRZYBYLOWSKI, Mark, BARTIDO, Shirley, BORQUEZ-OJEDA, Oriana, TAYLOR, Clare, YEH, Raymond, CAPACIO, Vanessa, OLSZEWSKA, Malgorzata, HOSEY, James

“…On the basis of promising preclinical data demonstrating the eradication of systemic B-cell malignancies by CD19-targeted T lymphocytes in vivo in severe…”
Get full text

CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience by Palomba, M Lia, Qualls, David, Monette, Sebastien, Sethi, Shenon, Dogan, Ahmet, Roshal, Mikhail, Senechal, Brigitte, Wang, Xiuyan, Rivière, Isabelle, Sadelain, Michel, Brentjens, Renier J, Park, Jae H, Smith, Eric L

“…BackgroundWaldenström macroglobulinemia (WM) is an incurable disease and, while treatable, can develop resistance to available therapies and be fatal. Chimeric…”
Get full text

Engineering strategies to overcome the current roadblocks in CAR T cell therapy by Rafiq, Sarwish, Hackett, Christopher S., Brentjens, Renier J.

“…T cells genetically engineered to express chimeric antigen receptors (CARs) have proven — and impressive — therapeutic activity in patients with certain…”
Get full text